NL-OMON42076
Recruiting
Not Applicable
A Phase 1, Open-label Clinical Study to Assess the Pharmacokinetics (Distribution, Metabolism,;and Excretion) of 14C-Vosaroxin in Patients with Advanced Solid Tumors - VOS-ADME-101
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- advanced solid tumors (ie, breast, lung, head/neck,colorectal, melanoma, and sarcoma)
- Sponsor
- Sunesis Pharmaceuticals, Inc.
- Enrollment
- 6
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Able to understand and provide written informed consent;
- •2\. At least 18 years old at the time of informed consent;
- •3\. Histologically or cytologically confirmed diagnosis of advanced solid tumors (ie, breast, lung, head/neck, colorectal, melanoma, and sarcoma). The malignancy must be considered unresponsive to accepted available therapies;
- •4\. ECOG performance status of 0, 1, or 2;
- •5\. Life expectancy of \>\= 3 months;
- •6\. Acceptable recovery from clinically significant nonhematologic toxicity after prior therapy;
- •7\. If female, must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative urine or serum pregnancy test within 14 days before randomization, and must agree to use an adequate method of contraception during the study until 30 days after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method;
- •of contraception during the study until 30 days after the last treatment;
- •8\. Adequate renal function (normal to mild dysfunction), with a serum creatinine value of \>1\.5 x the upper limit of normal (ULN) and with a calculated creatinine clearance (CLCR) of \>\=40 mL/minute;
- •9\. Adequate hepatic function defined as follows;
Exclusion Criteria
- •1\. Prior chemotherapy, radiotherapy, radioimmunotherapy, or immunotherapy within 28 days of the first dose of study treatment or has not recovered from adverse events (AEs) due to any agents administered previously;
- •2\. Presence of known brain metastases or active central nervous system (CNS) disease;
- •3\. Prior treatment with vosaroxin within 60 days of enrollment;
- •4\. Prior treatment with any hematopoietic growth factors within 14 days of study entry (patients on chronic erythropoiesis stimulating agents are allowed);
- •5\. New York Heart Association Class 3 or 4 heart disease, active ischemia, or any uncontrolled, unstable cardiac condition for which treatment for the condition is indicated but is not controlled despite adequate therapy, including angina pectoris, cardiac arrhythmia, hypertension, or congestive heart failure;
- •6\. Myocardial infarction within the previous 12 weeks;
- •7\. Active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment;
- •8\. Pregnant or lactating;
- •9\. Known positive test result for hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HC Ab) or has a known positive test result for human immunodeficiency virus (HIV) or a history of HIV disease.;10\. Presence of inflammatory bowel disease, occlusion of the gastrointestinal tract, significant constipation, or any condition resulting in clinically significant obstruction of the gastrointestinal tract.;11\. History of biliary obstruction or cholecystectomy.;12\. Any condition resulting in a clinically significant obstruction of the urinary tract.;13\. Known hypersensitivity to vosaroxin or any other components of the study treatment.;14\. Serious medical or psychiatric condition that, in the opinion of the Investigator, should preclude the patient from participating in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A Clinical study on quadrivalent Human Papilloma virus vaccineHealth Condition 1: Z23- Encounter for immunizationCTRI/2017/02/007785Serum Institute of India Pvt Ltd47
Completed
Phase 1
A clinical study to assess safety and tolerability of tetanus, diptheria, and pertussis vaccine in adults.Health Condition 1: Z23- Encounter for immunizationCTRI/2017/03/008003Serum Institute of India Pvt Ltd23
Recruiting
Phase 1
Clinical research of filling extraction sockets with selective COX2 inhibitor-containing paste in patients with mandibular wisdom tooth extractions.third molarwisdom tooth extractionD008964JPRN-jRCTs051230162Kakei Yasumasa12
Completed
Not Applicable
A phase I open-label clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced solid tumorsadvanced cancerAdvanced solid tumor10027655NL-OMON47883Vrije Universiteit Medisch Centrum27
Completed
Phase 1
Phase I clinical trial to evaluate the safety,tolerance and immune response ofChikungunya vaccine in healthy adults of 18 to 50 years ageCTRI/2020/04/024533Bharat Biotech International limited20